The Zhitong Finance App learned that Genting Xinyao B (01952) is now up more than 6%. As of press release, it has risen 5.47% to HK$27, with a turnover of HK$139 million.
According to the news, Genting Xinyao announced that in the important stage of implementing “independent development and successful commercialization of products based on mRNA platforms” two-wheel drive, the company appointed Ms. Zeng Qingwen as Chief Medical Officer and Mr. Liang Xu as Chief Product Officer to further strengthen the management team and enhance strategic integration between R&D, clinical development, medical affairs and marketing departments.
Furthermore, CBC Group, the controlling shareholder of Genting Xinyao Company, Luo Yongqing, the company's executive director and CEO, and He Ying, the company's executive director and chief financial officer, have notified the company that they each voluntarily promised not to sell any shares of the company directly or indirectly owned by them for at least six months, based on firm confidence in the company's future prospects and long-term development.